Critical Contrast: Seaport Therapeutics (SPTX) & The Competition

Seaport Therapeutics (NASDAQ:SPTX) is one of 906 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Seaport Therapeutics to related companies based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Seaport Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	6	0	2.36
Seaport Therapeutics Competitors	7705	13654	25540	992	2.41

Seaport Therapeutics currently has a consensus price target of $37.33, suggesting a potential upside of 42.22%. As a group, “Pharmaceuticals” companies have a potential upside of 28.81%. Given Seaport Therapeutics’ higher possible upside, equities research analysts plainly believe Seaport Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.0% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Seaport Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-2.17
Seaport Therapeutics Competitors	$3.50 billion	$3.13 billion	541.40

Seaport Therapeutics’ rivals have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Seaport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,303.77%	-221.68%	-17.78%

Summary

Seaport Therapeutics rivals beat Seaport Therapeutics on 7 of the 12 factors compared.

About Seaport Therapeutics

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.